The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety, efficacy, and pharmacokinetics (PK) of TS-1 combined with cisplatin in advanced cancer patients with severe hepatic dysfunction.
 
Yong Xiang Gwee
No Relationships to Disclose
 
Andrea Wong
Honoraria - AstraZeneca/Daiichi Sankyo; DKSH; Eisai; Novartis; Pfizer
Research Funding - Otsuka
 
Boon Cher Goh
No Relationships to Disclose
 
Ross Soo
No Relationships to Disclose
 
Wei-Peng Yong
Consulting or Advisory Role - Abbvie/Genentech; Amgen; Astellas Pharma; AstraZeneca
Speakers' Bureau - AstraZeneca; BMS; DKSH; Eisai; Merck KGaA; MSD Oncology; Taiho Oncology
Research Funding - Amgen (Inst); AstraZeneca (Inst); BMS (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Experimental Drug Development Centre (EDDC)/A*STAR (Inst); MSD (Inst); Novartis (Inst); SCG Cell Therapy (Inst)
 
David Tan
Stock and Other Ownership Interests - Asian Microbiome Library
Honoraria - AstraZeneca; Bayer; BioNTech SE; BMS; Daiichi Sankyo; Eisai; Foundation Medicine; GlaxoSmithKline; Merck; MSD; Roche; Zymeworks
Consulting or Advisory Role - AstraZeneca; Bayer; BMS; Daiichi Sankyo; Eisai; GlaxoSmithKline; Merck; MSD; Roche; Zymeworks
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Eisai; GlaxoSmithKline; Roche
Research Funding - AstraZeneca (Inst); Bayer (Inst); Experimental Drug Development Centre (EDDC)/A*STAR (Inst); Karyopharm Therapeutics (Inst); MSD (Inst); National Medical Research Council/Ministry of Health Singapore; National Medical Research Council/Ministry of Health Singapore (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Daiichi Sanyo; Merck; Novartis; Roche; Zymeworks
 
Cheng Ean Chee
No Relationships to Disclose
 
Hon Lyn Tan
No Relationships to Disclose
 
Yiqing Huang
No Relationships to Disclose
 
Yvonne Ang
No Relationships to Disclose
 
Wan Qin Chong
No Relationships to Disclose
 
Joline Lim
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; DKSH; Gilead Sciences; MSD; Novartis; Pfizer
Research Funding - CTI BioPharma Corp (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer
 
Gloria Chan
Honoraria - Roche
Travel, Accommodations, Expenses - AstraZeneca
 
Natalie Ngoi
Honoraria - AstraZeneca; MSD Oncology; Pfizer
Consulting or Advisory Role - MSD Oncology; Pfizer
Speakers' Bureau - MSD Oncology
Research Funding - iOnctura
Travel, Accommodations, Expenses - MSD Oncology
 
Samuel Ow
Honoraria - AstraZeneca; Lilly; Novartis; Pfizer
 
Joan Choo
No Relationships to Disclose
 
Rachel Wong
Consulting or Advisory Role - Novartis; Roche
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo/Astra Zeneca
 
Kenneth Sooi
No Relationships to Disclose
 
Ling-Zhi Wang
No Relationships to Disclose
 
Soo Chin Lee
Honoraria - AstraZeneca/Daiichi Sankyo; Eisai; MSD Oncology; Novartis; Pfizer; Roche; Sanofi
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Eisai; MSD Oncology; Novartis; Pfizer; Roche; Sanofi
Research Funding - Adagene; ASLAN Pharmaceuticals; Bayer; Eisai; Karyopharm Therapeutics; Pfizer; Taiho Pharmaceutical
Expert Testimony - Novartis
Travel, Accommodations, Expenses - ACT Genomics; AstraZeneca/MedImmune; Novartis; Pfizer; Roche